Uroxatral: Targeted Relief for Benign Prostatic Hyperplasia Symptoms
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.49 | $44.72 (0%) | 🛒 Add to cart |
| 60 | $1.22 | $89.44 $73.10 (18%) | 🛒 Add to cart |
| 90 | $1.13 | $134.16 $101.48 (24%) | 🛒 Add to cart |
| 120 | $1.03 | $178.88 $123.84 (31%) | 🛒 Add to cart |
| 180 | $0.95 | $268.32 $170.28 (37%) | 🛒 Add to cart |
| 270 | $0.86 | $402.48 $232.20 (42%) | 🛒 Add to cart |
| 360 | $0.77
Best per pill | $536.64 $278.64 (48%) | 🛒 Add to cart |
Synonyms | |||
Uroxatral (alfuzosin HCl) is a selective alpha-1 adrenergic receptor antagonist specifically indicated for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH). This medication works by relaxing smooth muscle in the prostate and bladder neck, improving urine flow and reducing BPH-related voiding difficulties. It represents a well-tolerated option with a favorable pharmacokinetic profile, offering rapid onset of action with once-daily dosing convenience. Clinicians value its uroselectivity, which minimizes cardiovascular effects while effectively addressing lower urinary tract symptoms.
Features
- Contains alfuzosin hydrochloride 10 mg as the active pharmaceutical ingredient
- Extended-release tablet formulation for consistent 24-hour plasma concentrations
- Selective alpha-1 adrenergic blockade with particular affinity for alpha-1A receptors
- Rapid onset of action with symptomatic improvement often within hours of first dose
- Does not require dose titration in most patients
- Can be taken with or without food (unlike some other alpha-blockers)
- Minimal effect on blood pressure in normotensive patients
- Lower incidence of orthostatic hypotension compared to non-selective alpha-blockers
Benefits
- Significant improvement in maximum urinary flow rate (Qmax) within 1-2 weeks
- Reduction in International Prostate Symptom Score (IPSS) by approximately 30-40%
- Decreased nocturia frequency and improved sleep quality
- Reduced urinary urgency and frequency during daytime hours
- Complete bladder emptying with decreased post-void residual volume
- Improved quality of life measures related to urinary symptoms
Common use
Uroxatral is primarily prescribed for the management of symptomatic benign prostatic hyperplasia in adult males. The medication addresses both obstructive symptoms (weak stream, hesitancy, intermittency, straining) and irritative symptoms (frequency, urgency, nocturia) associated with BPH. It is particularly suitable for patients who require rapid symptom relief while avoiding surgical intervention. Clinicians often prescribe Uroxatral as first-line pharmacotherapy for moderate to severe BPH symptoms, especially in patients with concomitant hypertension who may benefit from its minimal blood pressure effects.
Dosage and direction
The recommended dosage is one 10 mg extended-release tablet taken orally once daily, immediately after the same meal each day. Tablets should be swallowed whole and not crushed, chewed, or divided. Administration with food enhances bioavailability and ensures consistent absorption. Treatment response is typically evident within 2-4 weeks, with maximum benefit achieved by 8 weeks of continuous therapy. No dosage adjustment is required for elderly patients or those with renal impairment, though caution is advised in patients with severe hepatic impairment.
Precautions
Patients should be advised about the potential for dizziness, lightheadedness, or syncope, particularly with the initial dose or when increasing the dosage. Caution is warranted when driving or operating machinery until the patient’s response to treatment is established. Orthostatic hypotension may occur, especially in volume-depleted patients or those taking antihypertensive medications concurrently. Regular monitoring of blood pressure is recommended during treatment initiation. Patients should be advised to avoid sudden position changes from sitting or lying positions. Regular prostate examinations and monitoring of BPH symptoms are necessary to assess treatment efficacy and disease progression.
Contraindications
Uroxatral is contraindicated in patients with known hypersensitivity to alfuzosin hydrochloride or any component of the formulation. It must not be used in patients with moderate to severe hepatic impairment (Child-Pugh categories B and C). Concomitant use with strong CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, or clarithromycin is contraindicated due to significantly increased alfuzosin exposure. The medication is not indicated for use in women or children, and should not be used for treatment of hypertension.
Possible side effects
The most commonly reported adverse reactions (≥2% incidence) include dizziness (6.3%), upper respiratory tract infection (3.2%), headache (3.2%), and fatigue (3.0%). Less frequent side effects may include orthostatic hypotension (0.6%), syncope (0.1-0.3%), palpitations (1.0%), and gastrointestinal disturbances such as nausea, abdominal pain, or dyspepsia (1-2%). Sexual side effects including erectile dysfunction (0.6-1.5%) and decreased libido (0.3-0.8%) occur less frequently than with 5-alpha reductase inhibitors. Most adverse effects are mild to moderate in severity and often diminish with continued therapy.
Drug interaction
Uroxatral undergoes extensive hepatic metabolism primarily via CYP3A4 enzymes, creating significant interaction potential. Concomitant use with strong CYP3A4 inhibitors is contraindicated. Moderate CYP3A4 inhibitors (erythromycin, diltiazem, verapamil) may increase alfuzosin exposure requiring careful monitoring. Concurrent administration with other alpha-adrenergic blocking agents may potentiate hypotensive effects. Additive blood pressure lowering may occur with antihypertensive medications, diuretics, nitrates, and phosphodiesterase-5 inhibitors. Caution is advised when combining with medications that prolong QT interval. No clinically significant interactions have been observed with atenolol, digoxin, or warfarin.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day with food. If the missed dose is not remembered until the next day, the patient should skip the missed dose and resume the regular dosing schedule. Double doses should not be taken to make up for a missed dose. Patients should be advised to maintain consistent timing of administration relative to meals to ensure optimal drug absorption and maintain steady-state concentrations.
Overdose
Alfuzosin overdose may manifest as pronounced alpha-adrenergic blockade effects including severe hypotension, cardiovascular collapse, and syncope. Supportive care should include immediate cardiovascular monitoring and stabilization. Treatment is primarily symptomatic and supportive, with maintenance of blood pressure through intravenous fluids and vasopressors if necessary. Patient positioning with legs elevated may be beneficial. Hemodialysis is unlikely to be effective due to high protein binding (82-90%) and extensive metabolism. Gastric lavage or activated charcoal may be considered if ingestion was recent.
Storage
Store at controlled room temperature 20-25°C (68-77°F) with excursions permitted between 15-30°C (59-86°F). Tablets should be kept in their original container with the lid tightly closed to protect from moisture and light. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Proper disposal of unused medication should follow local regulations, typically through medication take-back programs.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Treatment decisions should be made by qualified healthcare professionals based on individual patient assessment. Patients should not alter or discontinue medication without consulting their prescribing physician. While every effort has been made to ensure accuracy, medical knowledge evolves and prescribing information may change. Healthcare providers should consult the most current prescribing information before initiating therapy.
Reviews
Clinical studies demonstrate that Uroxatral provides significant improvement in BPH symptoms with favorable tolerability. In randomized controlled trials, 67-72% of patients experienced clinically meaningful improvement in IPSS scores compared to 45-48% with placebo. Urologists report particular satisfaction with its rapid onset of action and minimal blood pressure effects in normotensive patients. Patients frequently report improved quality of life measures, especially regarding reduced nocturia and improved sleep patterns. The once-daily formulation receives positive feedback for convenience and adherence compared to multiple-dose regimens. Long-term studies show maintained efficacy over 2 years of continuous treatment with stable safety profile.